Names | |
---|---|
IUPAC name
2-(2-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl)-1H-indole | |
Other names
GX15-070 | |
Identifiers | |
| |
3D model (JSmol) |
|
ChemSpider | |
PubChem CID |
|
UNII |
|
| |
| |
Properties | |
C20H19N3O | |
Molar mass | 317.392 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals.[1] Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.[2][3][4]
Obatoclax is an inhibitor of the Bcl-2 familyofproteins.[5] This inhibition induces apoptosis in cancer cells, preventing tumor growth. Solubility has been an issue in the development of the drug.[6]
Clinical trial results have been published for treatment of acute myeloid leukemia,[7] small cell lung cancer,[8] Hodgkin's lymphoma,[9] and myelodysplastic syndromes.[10]
Teva halted a phase III trial in patients with lung cancer before it had begun, citing "business decisions" as the reason.[11]